- Home
- OCGN vs GNLX Comparison
OCGN vs GNLX Comparison
Compare OCGN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- GNLX
- Stock Information
- Founded
- OCGN 2013
- GNLX 2001
- Country
- OCGN United States
- GNLX United States
- Employees
- OCGN N/A
- GNLX N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- GNLX Health Care
- Exchange
- OCGN Nasdaq
- GNLX Nasdaq
- Market Cap
- OCGN 189.6M
- GNLX 184.4M
- IPO Year
- OCGN N/A
- GNLX 2023
- Fundamental
- Price
- OCGN $0.68
- GNLX $2.63
- Analyst Decision
- OCGN Strong Buy
- GNLX Strong Buy
- Analyst Count
- OCGN 3
- GNLX 4
- Target Price
- OCGN $6.33
- GNLX $18.25
- AVG Volume (30 Days)
- OCGN 4.3M
- GNLX 233.3K
- Earning Date
- OCGN 05-13-2025
- GNLX 05-08-2025
- Dividend Yield
- OCGN N/A
- GNLX N/A
- EPS Growth
- OCGN N/A
- GNLX N/A
- EPS
- OCGN N/A
- GNLX N/A
- Revenue
- OCGN $4,054,999.00
- GNLX $8,000.00
- Revenue This Year
- OCGN N/A
- GNLX N/A
- Revenue Next Year
- OCGN N/A
- GNLX N/A
- P/E Ratio
- OCGN N/A
- GNLX N/A
- Revenue Growth
- OCGN N/A
- GNLX N/A
- 52 Week Low
- OCGN $0.52
- GNLX $1.60
- 52 Week High
- OCGN $2.06
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- OCGN 51.84
- GNLX 42.31
- Support Level
- OCGN $0.64
- GNLX $2.30
- Resistance Level
- OCGN $0.74
- GNLX $2.68
- Average True Range (ATR)
- OCGN 0.07
- GNLX 0.26
- MACD
- OCGN 0.00
- GNLX 0.05
- Stochastic Oscillator
- OCGN 54.50
- GNLX 55.49
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.